Butyrate trials

Maria Domenica Cappellini, Giovanna Graziadei, Laura Ciceri, Alessia Comino, Paolo Bianchi, Mauro Pomati, Gemino Fiorelli

Research output: Contribution to journalArticle

Abstract

The aims of this study were to ascertain tolerability, safety and efficacy of oral isobutyramide (150 mg/kg bw/day) in stimulating fetal hemoglobin production in twelve thalassemia intermedia patients. Patients were treated for 28 days and followed for a further 28 days. Efficacy was monitored by non-α/α globin chain ratio and percentage of HbF. Five patients experienced increases of non-α/α ratio ranging between 5.3 and 100% at the end of treatment. Five patients show an increase of HbF ranging between 4.4 and 26%. Their HbF% continues to increase during follow-up period. The analysis of variance for HbF showed a time effect close to significance both in treatment period (p = 0.06) and in follow up period (p = 0.08). Moreover, to evaluate a possible erythropoietic modification, serum Erythropoietin (sEpo) and serum Transferrin Receptor (sTfR) were evaluated. Serum Epo and sTfR levels were significantly increased during treatment (p <0.05 vs baseline).

Original languageEnglish
Pages (from-to)110-119
Number of pages10
JournalAnnals of the New York Academy of Sciences
Volume850
DOIs
Publication statusPublished - 1998

Fingerprint

Transferrin Receptors
Butyrates
Fetal Hemoglobin
Globins
Erythropoietin
Analysis of variance (ANOVA)
Serum
beta-Thalassemia
Analysis of Variance
Therapeutics
Safety
isobutyramide
Efficacy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Butyrate trials. / Cappellini, Maria Domenica; Graziadei, Giovanna; Ciceri, Laura; Comino, Alessia; Bianchi, Paolo; Pomati, Mauro; Fiorelli, Gemino.

In: Annals of the New York Academy of Sciences, Vol. 850, 1998, p. 110-119.

Research output: Contribution to journalArticle

Cappellini, Maria Domenica ; Graziadei, Giovanna ; Ciceri, Laura ; Comino, Alessia ; Bianchi, Paolo ; Pomati, Mauro ; Fiorelli, Gemino. / Butyrate trials. In: Annals of the New York Academy of Sciences. 1998 ; Vol. 850. pp. 110-119.
@article{abe8d472db554d4b8f94d3928b6ee9a3,
title = "Butyrate trials",
abstract = "The aims of this study were to ascertain tolerability, safety and efficacy of oral isobutyramide (150 mg/kg bw/day) in stimulating fetal hemoglobin production in twelve thalassemia intermedia patients. Patients were treated for 28 days and followed for a further 28 days. Efficacy was monitored by non-α/α globin chain ratio and percentage of HbF. Five patients experienced increases of non-α/α ratio ranging between 5.3 and 100{\%} at the end of treatment. Five patients show an increase of HbF ranging between 4.4 and 26{\%}. Their HbF{\%} continues to increase during follow-up period. The analysis of variance for HbF showed a time effect close to significance both in treatment period (p = 0.06) and in follow up period (p = 0.08). Moreover, to evaluate a possible erythropoietic modification, serum Erythropoietin (sEpo) and serum Transferrin Receptor (sTfR) were evaluated. Serum Epo and sTfR levels were significantly increased during treatment (p <0.05 vs baseline).",
author = "Cappellini, {Maria Domenica} and Giovanna Graziadei and Laura Ciceri and Alessia Comino and Paolo Bianchi and Mauro Pomati and Gemino Fiorelli",
year = "1998",
doi = "10.1111/j.1749-6632.1998.tb10468.x",
language = "English",
volume = "850",
pages = "110--119",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Butyrate trials

AU - Cappellini, Maria Domenica

AU - Graziadei, Giovanna

AU - Ciceri, Laura

AU - Comino, Alessia

AU - Bianchi, Paolo

AU - Pomati, Mauro

AU - Fiorelli, Gemino

PY - 1998

Y1 - 1998

N2 - The aims of this study were to ascertain tolerability, safety and efficacy of oral isobutyramide (150 mg/kg bw/day) in stimulating fetal hemoglobin production in twelve thalassemia intermedia patients. Patients were treated for 28 days and followed for a further 28 days. Efficacy was monitored by non-α/α globin chain ratio and percentage of HbF. Five patients experienced increases of non-α/α ratio ranging between 5.3 and 100% at the end of treatment. Five patients show an increase of HbF ranging between 4.4 and 26%. Their HbF% continues to increase during follow-up period. The analysis of variance for HbF showed a time effect close to significance both in treatment period (p = 0.06) and in follow up period (p = 0.08). Moreover, to evaluate a possible erythropoietic modification, serum Erythropoietin (sEpo) and serum Transferrin Receptor (sTfR) were evaluated. Serum Epo and sTfR levels were significantly increased during treatment (p <0.05 vs baseline).

AB - The aims of this study were to ascertain tolerability, safety and efficacy of oral isobutyramide (150 mg/kg bw/day) in stimulating fetal hemoglobin production in twelve thalassemia intermedia patients. Patients were treated for 28 days and followed for a further 28 days. Efficacy was monitored by non-α/α globin chain ratio and percentage of HbF. Five patients experienced increases of non-α/α ratio ranging between 5.3 and 100% at the end of treatment. Five patients show an increase of HbF ranging between 4.4 and 26%. Their HbF% continues to increase during follow-up period. The analysis of variance for HbF showed a time effect close to significance both in treatment period (p = 0.06) and in follow up period (p = 0.08). Moreover, to evaluate a possible erythropoietic modification, serum Erythropoietin (sEpo) and serum Transferrin Receptor (sTfR) were evaluated. Serum Epo and sTfR levels were significantly increased during treatment (p <0.05 vs baseline).

UR - http://www.scopus.com/inward/record.url?scp=0031850654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031850654&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.1998.tb10468.x

DO - 10.1111/j.1749-6632.1998.tb10468.x

M3 - Article

C2 - 9668533

AN - SCOPUS:0031850654

VL - 850

SP - 110

EP - 119

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -